Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Aroxybutynin and Atomoxetine · AD109

Small molecule · developed by Apnimed

Phase 3 Most advanced trial
APMD Developer
1 Registered trials

What is Aroxybutynin and Atomoxetine?

Aroxybutynin and Atomoxetine (AD109) is a combination drug studied in obstructive sleep apnea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AD109
Drug type
Small molecule
Therapy area
Respiratory
Developer
Apnimed (APMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06566820 Phase 3 OSA Enrolling by invitation APMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

OSA

More from Apnimed

AD036 Phase 2 AD109 Phase 3 AD113 Phase 2 AD182 Phase 2 AD313 Phase 1/2 AD504 Phase 2

Follow APMD, the company behind Aroxybutynin and Atomoxetine

See APMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.